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Received April 25, 2011; accepted September 9, 2011AbstractBackground: The population of uremia patients receiving long-term peritoneal dialysis (PD) is growing, and abnormal thyroid function occurs
increasingly in patients with chronic kidney disease in comparison with the normal population. We aimed to elucidate the clinical impact of
abnormal thyroid function in long-term PD patients.
Methods: This was a retrospective, case-controlled, longitudinal study. We collected the characteristics, laboratory data, dialysis parameters, and
thyroid and heart function of patients who underwent long-term PD for >8 years during the past 25 years in Taipei Veterans General Hospital,
Taiwan. Patients with hyperthyroidism were excluded. None of these subjects presented a recent history of infection or inflammatory disease or
took any drugs known to influence thyroid function. Abnormal thyroid function was defined as the presence of primary hypothyroidism and sick
euthyroid syndrome.
Results: A total of 46 patients were enrolled. The mean duration of PD therapy was 147.8 (48.3) months. Nineteen of 46 (41.3%) patients had
abnormal thyroid function tests. Patients with abnormal thyroid function had a worse prognosis in cumulative patient survival analysis by
KaplaneMeier method ( p ¼ 0.02). After adjusting for diabetes mellitus, cardiothoracic ratio, C-reactive protein (CRP), and cardiovascular
diseases, abnormal thyroid function remained as an independent predictor of patient survival (hazard ratio ¼ 7.633, 95% confidence interval
1.3e43.9, p ¼ 0.02). The CRP levels were significantly inversely correlated with free thyroxine levels (r ¼ e0.547; p ¼ 0.01). The most
common cause of death among the patients was sepsis (67.7%) rather than cardiovascular disease (20.0%).
Conclusion: PD patients with abnormal thyroid function had poor cumulative survival. Lower thyroid hormone level in PD patients was
associated with high CRP levels. Physicians should be alert for the presence of abnormal thyroid function and proinflammatory status in long-
term PD patients.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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The peritoneal dialysis (PD) survival rate has been reported
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doi:10.1016/j.jcma.2011.12.006PD patients is 70% in Japan. Type 2 diabetes mellitus (DM) is
a common cause of end-stage renal disease (ESRD) and is
a predictor of PD patient survival.4 Cardiovascular disease
(CVD) is also the leading cause of mortality in patients with
ESRD. Coronary artery calcification is being increasingly
recognized in PD patients with multiple risk factors, including
inflammation and malnutrition.5 In addition, dialysis patients
also show low free triiodothyronine (T3) levels, which are
caused by a diminished peripheral conversion of thyroxinehinese Medical Association. All rights reserved.
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previous epidemiology study has shows that increased preva-
lence of hypothyroidism in patients with ESRD requires
hemodialysis.7 In addition, hypothyroidism is increased in
patients with reduced glomerular filtration rate, from 5.3% to
20% in patients with estimated glomerular filtration rate
<60 mL/minute/1.73 m2. The presence of goiter is also
correlated with duration of treatment of PD patients.8
Thus, the aim of the present study was to evaluate the
following aspects in long-term PD patients: (1) factors
affecting patient survival; and (2) the relationships between
thyroid hormone levels, micro-inflammation status, and
cardiac function.
2. Methods2.1. SubjectsWe included those patients who had received PD therapy
for >8 years between January 1, 1986 and September 30,
2010 in Taipei Veterans General Hospital, Taiwan. All the
patients chose PD as the first modality for renal replacement
therapy. The exclusion criteria included absence of data of
thyroid function, hyperthyroidism, or having received thyroid
hormone replacement. Finally, seven patients who were
missing data of thyroid function were not included, and a total
of 46 patients were enrolled in this retrospective study. None of
the patients had residual renal function or psychiatric illness,
or were receiving specific medication, including dopamine,
glucocorticoid or phenytoin, that might affect thyroid function.
Those who discontinued PD therapy after 8 years by shifting to
hemodialysis (HD) or receiving a kidney transplant were
censored. The research project was approved by the Institu-
tional Review Board of Taipei Veterans General Hospital.2.2. Demographics and blood samplingTo analyze the overall patient survival rate during the
25-year period, the following data were collected: sex, patient
age at initial PD, presence of underlying renal disease,
comorbidity, follow-up duration, cause of death, left and right
ventricle ejection fractions, cardiothoracic ratio (CRT), rate of
peritonitis (number of episodes/patientemonths), and serum
biochemical data. To assess underlying renal disease, patient
history of chronic glomerular disease or interstitial disease was
reviewed. To assess comorbidity, patient history of DM, CVD,
and hypertension was examined. CVD was defined as a history
of coronary, cerebrovascular, or peripheral vascular disease.
Free T4, thyroid stimulating hormone (TSH), T3, left and right
ventricle ejection fraction, and plain chest film were checked
3 months after the initiation of PD and followed by annual
check-up; all these tests were parts of the routine in our
Nephrology Department. The first single measurement of
thyroid function was recorded as the data for statistical anal-
ysis. Peritoneal equilibration test was performed 1 month after
the initiation of PD. The causes of discontinuation of PD or
death were also recorded.2.3. Laboratory testsAbnormal thyroid function was defined as the presence of
hypothyroidism: (1) subclinical hypothyroidism (TSH > 4.0
mIU/mL and normal levels of free T4 or free T4 < 0.59 ng/dL
and normal TSH); or (2) overt hypothyroidism (free T4 < 0.59
ng/dL and TSH > 4 mIU/mL); or sick euthyroid syndrome: (1)
low T4 syndrome (T4 < 4.5 mg/dL); or (2) low T3 syndrome
(T3 < 95 ng/dL and normal levels of free T4 and TSH). The
serum biochemical analysis included assessment of: hemato-
crit, serum albumin, serum creatinine, intact parathyroid
hormone, normalized protein catabolic rate, peritoneal urea
clearance (Kt/V urea), C-reactive protein (CRP), total T4
(SPAC T4 RIA Kit, Daiichi, Tokyo, Japan), total T3 (SPAC
T3 RIA Kit; Incstar Corp., Stillwater, MN, USA), free T4
[GammaCoat Free T4 (two-step) 125I RIA Kit; Incstar Corp.],
and TSH (GammaCoat hTSH 125I IRMA Kit; Incstar Corp.).
The intra- and inter-assay coefficients of variation were 1.5%
and 4.8% for TSH, 5.9% and 6.6% for T3, 3.3% and 5.0% for
free T4, and 4.5% and 5.1% for T4, respectively. The sensi-
tivities were 0.03 mIU/mL for TSH, 0.5 pg/mL for free T4,
0.025 mg/dL for T4, and 7 ng/dL for T3, respectively. Serum
intact parathyroid hormone (i-PTH) level was measured using
the N-tact PTH SP Kit (Incstar Corp.). The CTR was calcu-
lated as the ratio of the largest horizontal diameter of the heart
divided by the largest internal diameter of the thorax wall on
chest radiography. The ejection fraction of left and right
ventricles was measured via radionuclide ventriculography.
The reference ranges of the parameters were as follows:
T4 ¼ 4.5e11.0 mg/dL; T3 ¼ 95e205 ng/dL; free T4 ¼
0.59e1.81 ng/dL; TSH ¼ 0.25e4.0 mIU/mL; i-PTH ¼
10e57 pg/mL; ferritin ¼ 30e400 ng/mL; high sensitivity
CRP < 0.5 mg/dL; and CTR < 0.5. Serum biochemical
parameters were measured using a computerized automated
analyzer (Hitachi 736-60, Tokyo, Japan).2.4. Statistical analysisWe performed statistical analyses using SPSS version 17.0
(SPSS Inc., Chicago, IL, USA). Pearson’s c2 test was used to
analyze the categorical variables between the groups. An
independent-samples t test was used to analyze the clinical and
biochemical parameters of the groups, and the KaplaneMeier
method was used to analyze patient survival rate. Relation-
ships between paired parameters were evaluated via Pearson
correlation coefficients. We analyzed the hazard ratios using
backward logistic regressions of the Cox proportional hazards
method. Independent variables were selected for multivariate
analysis if they had a p value < 0.15 in the univariate analysis.
The level of significance was set at 0.05 for all tests.
3. Results3.1. Patient characteristicsA total of 46 patients were enrolled for this study. The
mean age at initiation of PD was 44 years (standard deviation,
Table 1
Baseline demographic characteristics in PD patients according to the status of
thyroid function (n ¼ 46).
Abnormal thyroid
function (n ¼ 19)
Normal thyroid
function (n ¼ 27)
p
Median age at PD initiation (y) 46.57 (27e67) 42.22 (14e68) 0.23
Sex Male (%) 12 (63.0) 12 (44.4) 0.24
Median duration of PD (mo) 141.21 (96e212) 157.85 (96e300) 0.25
Cause of ESRD
CGN, including DM (%) 7 (38.9) 9 (42.9) NS
CIN (%) 7 (38.9) 9 (42.9) NS
Others (%) 4 (22.2) 3 (14.7) 0.68
Comorbidity
DM (%) 4 (21.1) 7 (13.5) NS
CVD (%) 3 (15.8) 4 (15.4) NS
HTN (%) 11 (61.1) 14 (60.9) NS
CHF (%) 2 (12.5) 6 (28.6) 0.43
Abnormal thyroid function includes subclinical hypothyroidism and sick
euthyroid syndrome.
CGN ¼ chronic glomerulonephritis; CHF ¼ congestive heart failure; CIN ¼
chronic interstitial disease; CVD ¼ cardiovascular disease; DM ¼ diabetes
mellitus; ESRD ¼ end-stage renal disease; HTN ¼ hypertension; PD ¼
peritoneal dialysis.
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duration of PD was 147.8 months (standard deviation, 48.3
months; median, 132 months; range, 96e298 months). Nine-
teen of the 46 (41.3%) patients had abnormal thyroid function
tests. The frequency of abnormal thyroid function in these 46
patients was 20.9% for low T3, 25.5% for high TSH, 11.6%
for low free T4, and 9.3% for low T4. Presence of hypothy-
roidism including subclinical hypothyroidism accounted for
28.2%, and sick euthyroid syndrome including free T3 or T4
syndrome accounted for 13.0%. Basic demographic data were
not statistically different between the study and control groups
regarding age at initiation of PD, duration of PD therapy, sex,
and underlying disease (Table 1).Table 2
Comparison of baseline clinical parameters in PD patients according to the status
Abnormal thyroid
LVEF (%) 58.93 (43e81)
RVEF (%) 53.61 (40e73)
CRT 0.50 (0.42e0.63)
Initial T3 (ng/dL) 93.13 (56.62e147
Initial T4 (mg/dL) 5.03 (2.12e7.83)
Initial free T4 (ng/dL) 1.03 (0.39e1.42)
Initial TSH (mIU/mL) 6.51 (0.95e47.00
Peritoneal equilibration test 0.63 (0.45e0.85)
Peritoneal Kt/V urea (/wk) 2.05 (1.38e2.56)
Total weekly creatinine clearance [L/(wk∙1.73 m2)1] 53.10 (31.98e86.
Normalized protein catabolic rate [g/(kg∙day)1] 1.00 (0.70e1.44)
Albumin (g/dL) 3.62 (2.9e4.2)
iPTH (pg/mL) 232.8 (71.55e665
Hematocrit (%) 31.53 (22.20e37.
Ca  P product 42.66 (25.56e69.
CRP (mg/dL) 1.27 (0.07e6.5)
Ferritin (ng/mL) 486.2 (66.5e1103
Peritonitis (episodes/patientemonths) 35.94 (0e113)
CRP ¼ C-reactive protein; CRT ¼ cardiothoracic ratio; iPTH ¼ intact parathyroid
ejection fraction; T3 ¼ triiodothyronine; T4 ¼ thyroxine; TSH ¼ thyroid stimulat
* Abnormal thyroid function includes subclinical hypothyroidism and sick euthy3.2. Patients’ clinical parametersIn the laboratory data, T3, T4, and TSH levels were signif-
icant lower in the patients with abnormal thyroid function
( p ¼ 0.02, 0.02, and 0.01, respectively). Left ventricular
ejection fraction (LVEF) and peritoneal Kt/V were not signif-
icantly different between the two groups ( p ¼ 0.05). There
were also no significant differences between the two groups
when considering all other clinical parameters including levels
of albumin, hemoglobin, ferritin, right ventricle ejection, and
peritonitis rate (Table 2).3.3. Patient survival analysisThe cumulative survival rate in patients with abnormal
thyroid function was shown by the KaplaneMeier method
(Fig. 1). Abnormal thyroid function was a significant predictor
of patient survival (log rank, p ¼ 0.02). In Cox proportional
hazards analysis and logistical regression analysis, as shown in
Table 3, age, DM, CVD and abnormal thyroid function were
all significant predictors of cumulative patient mortality.
Abnormal thyroid function (hazard ratio ¼ 7.633, 95%
confidence interval ¼ 1.328e43.889, p ¼ 0.02) was an inde-
pendent predictive factor in logistic regression. The subgroup
analysis of patients with hypothyroidism, including subclinical
or overt, and sick euthyroid syndrome, including low T3 or T4
syndrome, by univariate Cox proportional hazards analysis
showed no significance ( p ¼ 0.41 and 0.10, respectively; data
not shown).3.4. Factors related to free T4 levels and LV systolic
functionBivariate correlation analyses revealed that free T4 levels
were inversely associated with LVEF (r ¼ e0.245; p ¼ 0.06),of thyroid function* (n ¼ 46).
function (n ¼ 19) Normal thyroid function (n ¼ 27) p
52.10 (23e69) 0.05
52.06 (30e64) 0.64
0.50 (0.42e0.64) NS
.0) 112.84 (91.96e173.0) 0.02
6.44 (2.8e8.49) 0.02
1.16 (0.55e1.62) 0.14
) 1.76 (0.01e3.95) 0.01
0.70 (0.49e0.92) 0.07
2.22 (1.65e2.74) 0.05
00) 55.92 (34.00e77.63) 0.47
0.96 (0.53e1.70) 0.54
3.72 (2.8e4.4) 0.39
.0) 305.6 (2.1e1231) 0.38
38) 31.65 (22.20e50.00) NS
96) 49.31 (21.69e79.00) 0.07
0.80 (0.05e2.41) 0.24
) 461.2 (49.2e1973) 0.86
13.50 (0e26) 0.63
hormone; LVEF ¼ left ventricular ejection fraction; RVEF ¼ right ventricular
ing hormone.
roid syndrome.
Fig. 1. Cumulative patient survival determined using the KaplaneMeier
method. Cumulative survival of peritoneal dialysis patients (n ¼ 46) with
normal thyroid function (line I, dotted line; n ¼ 27) and abnormal thyroid
function (including subclinical hypothyroidism or sick euthyroid syndrome)
(line II, black line; n ¼ 19).
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levels (r ¼ e0.33; p ¼ 0.02), and CTR (r ¼ 0.266; p ¼ 0.04;
Fig. 2). Only CRP levels and CTR showed significant corre-
lation with free T4 levels. In multivariate linear regression,
CRP levels (b ¼ e0.547; p < 0.01) showed significant inverse
correlation with free T4 levels, after controlling for age, DM,
CVD, albumin, LVEF and CRP (Table 4).3.5. Patient outcomeBy the end of the study, 28 (65.1%) patients were still alive,
and 15 (34.9%) patients had died. Septic shock accounted for
10 of 15 (66.7%) of the cases of mortality, sudden cardiac
death accounted for three of 15 (20%), and the other two
patients died from respiratory failure or peripheral arterial
occlusive disease. All of the patients were still undergoing PD
therapy when they died. Seventeen of 28 living patients
continued PD therapy, but the other 11 discontinued PD. Eight
of 11 (72%) patients had shifted to HD and three (28%) had
undergone kidney transplantation. Only one (1.9%) patientTable 3
Cox proportional hazard model for the analysis of factors associated with mortalit
Variable (reference group)
Age (per 1 yr)
Diabetes mellitus (hazard for nondiabetic patients ¼ 1.0)
Cardiomegaly (CTR > 0.5) (hazard for CTR < 0.5 ¼ 1.0)
Abnormal thyroid function (hazard for normal thyroid function patients ¼ 1.0)
Inflammation status (CRP > 0.6) (hazard for CRP < 0.6 ¼ 1.0)
CVD (hazard for non-CVD patients ¼ 1.0)
CI ¼ confidence interval; CTR ¼ cardiothoracic ratio; CRP ¼ C-reactive protein;
* Independent variables except age were selected for multivariate analysis if thedeveloped encapsulating peritoneal sclerosis after 13 contin-
uous years of PD therapy.
4. Discussion
This case-controlled longitudinal study demonstrated that
PD patients with abnormal thyroid function had a shorter
cumulative survival in a long-term observation period. In our
study group, age, sex, duration of PD, comorbidity, Kt/V,
peritoneal equilibrium test (PET), left ventricular ejection
fraction (LVEF), and serum CRP and albumin levels showed
no significant difference, but thyroid function tests did differ
significantly (Tables 1 and 2). Compared with another cohort
study in Korea,3 our patients were younger and had lower
peritonitis rate. A high percentage (41.3%) of abnormal
thyroid dysfunction was demonstrated in our study. However,
Kang et al9 have reported that the percentage of subclinical
hypothyroidism in continuous ambulatory PD (CAPD)
patients was 27.5%, and the total percentage of hypothy-
roidism (excluding sick euthyroid syndrome) in our study was
similar at 26.0%. In addition, there was an increasing
frequency of having low T3 for patients in a later stage of
chronic kidney disease (CKD); up to 20% in CKD stage 3.7
The frequency of abnormal thyroid function in this long-
term study was similar to that in other studies.7,8
Patients diagnosed with ESRD had a higher chance of
developing primary hypothyroidism with lower free T4 levels
than the normal population had.10 Primary subclinical hypo-
thyroidism with high TSH levels but normal T4 or T3 levels is
relatively common in patients with CKD but not requiring
dialysis.11 The reason for the high percentage of high TSH or
low T3 levels among the PD patients was not clear, but
abdominal protein loss through PD exchange may be one
reason.12 Furthermore, low levels of T3 in ESRD patients
showed highly significant correlation with the level of
inflammatory markers interleukin-6 and CRP, and both were
independent predictors of death in HD patients.13 The reason
for patients with low T3 syndrome but without TSH elevation
is not dysfunction of the hypothalamo-pituitary axis because
truly hypothyroid patients with renal failure can still mount
a high TSH response.14 Inflammation may precipitate CKD or
ESRD patients into the development of abnormal thyroid
function. Low T3 levels were correlated with all-causey in PD patients (n ¼ 46).
Univariate Multivariate*
HR 95% CI p HR 95% CI p
1.124 1.057e1.194 <0.01 d d d
4.478 1.557e12.878 <0.01 4.066 1.093e15.123 0.03
4.271 0.945e19.303 0.05 d d d
3.632 1.196e11.027 0.03 7.633 1.328e43.889 0.02
3.105 0.863e11.178 0.08 d d d
3.542 1.248e10.054 0.01 8.447 1.687e42.291 <0.01
CVD ¼ cardiovascular disease; HR ¼ hazard ratio; PD ¼ peritoneal dialysis.
y had a p value <0.15 in the univariate analysis.
Fig. 2. Factors related to free thyroxine levels. Left ventricle ejection fraction (A; r ¼ e0.245, p ¼ 0.06); right ventricle ejection fraction (B; r ¼ e0.258,
p ¼ 0.06); C-reactive protein (C; r ¼ e0.33, p ¼ 0.02); and cardiothoracic ratio (D; r ¼ 0.266, p ¼ 0.04).
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biochemical euthyroid status. In addition to low T3 syndrome,
subclinical hypothyroidism was also found to be significantly
correlated with patient survival. This finding could be
explained by the negative inotropic effect of hypothyroidism
on LV systolic function in PD patients, and it could be sup-
ported by the report by Kang et al,9 who have also demon-
strated that TSH is negatively correlated with LVEF.
Low-T3 syndrome has commonly been interpreted by the
medical community as sick euthyroid syndrome. The etiology
of low T3 syndrome is decreased conversion of T4 to T3 (the
active form) by acute inhibition of I 50 deiodinase due to acute
illness. Low T3 syndrome is also a strong predictor of death in
patients with heart disease. In patients selected for coronary
angiography, free T3 levels are inversely correlated with the
presence of coronary artery disease and adverse prognosis.15
Low T3 is associated with left ventricular dysfunction andTable 4
Multivariate linear regression for free T4.
Free T4 p value
b
Age (y) 0.28 0.88
Diabetes mellitus 0.115 0.54
Cardiovascular disease 0.273 0.18
Cardiothoracic index 0.389 0.07
CRP (mg/dL)a 0.547 0.01
Albumin (g/dL) 0.153 0.54
Free T4 (ng/dL) d d
Left ventricular ejection fraction (%) 0.002 0.99
CRP ¼ C-reactive protein; T4 ¼ thyroxine.
a by Pearson correlation coefficients.left ventricular hypertrophy in ESRD patients.16 In addition,
the presence of inflammation and malnutrition was associated
with valvular calcification, and prolonged PD may enhance
aortic valve calcification.17 Furthermore, CRP is an important
precipitating factor associated with the abdominal calcification
index in HD patients.18 Christ-Crain et al19 reported that CRP
levels were insignificantly correlated with free T4 levels;
a trend of elevated CRP in subclinical or overt hypothyroidism
patients was detected. Demirci et al20 found high CTR and
CRP levels in fluid-overloaded PD patients, which means that
a higher CRP may jeopardize cardiac function. In our study,
free T4 levels were inversely correlated with CRP, and higher
free T4 levels showed an insignificant trend towards depressed
LVEF; a finding different from the results of others studies of
L-thyroxine supplement in subclinical hypothyroidism.21,22
It is surprising that we found that a much higher mortality
was caused by septic shock (66.7%) than cardiovascular
events (20%). In another large retrospective study, immediate
cause of death from cardiovascular events accounted for
41.2% and peritonitis was directly implicated in 15.2% of the
overall deaths.23 This discrepancy could be explained as
follows. First, lower free T4 levels significantly correlated
with higher CRP levels in our study, but not LVEF. That means
that abnormal thyroid function may not cause deterioration of
heart function. Second, these patients who had undergone
long-term PD were younger and may have had lower
frequency of vascular calcification or atherosclerosis than the
total group of PD patients.
There were several limitations to this study. First, this was
a single-center case-controlled study. Also, we selected
younger patients with lower peritonitis rates and
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larger population and multicenter cohort study is warranted to
obtain a clearer picture regarding the factors involved in the
long-term outcomes of PD. Second, only systolic but not
diastolic heart function was evaluated. We know that diastolic
dysfunction is also an important cause of heart failure in CKD
patients. Third, we did not analyze inflammatory markers
other than CRP (such as interleukin-6 or intercellular adhesion
molecule-1), and we did not set a clear definition of inflam-
matory status for our patients.
In conclusion, this study showed that abnormal thyroid
function in CAPD patients predicted a shorter cumulative
patient survival. Lower thyroid hormone levels were signifi-
cantly associated with higher CRP levels. In addition,
compared with cardiovascular events, sepsis was an even more
important issue with regard to the mortality of long-term PD
patients. Our study demonstrates the association of abnormal
thyroid function with CRP for PD patients in a long-term case-
controlled study. Clinical nephrologists should be alert to the
change in thyroid function parameters (including free T4,
TSH, T3 and T4 levels) and detect the possible underlying
mechanism of abnormal thyroid function such as proin-
flammatory status in CAPD patients as early as possible.
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